Gain Therapeutics (NASDAQ:GANX – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.16, Fidelity Earnings reports. Gain Therapeutics had a negative return on equity of 33.77% and a negative net margin of 8,470.12%. Shares of […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 37,500 shares, a decline of 42.0% from the February 13th total of 64,700 shares. Based on an average trading volume of 55,100 shares, the days-to-cover ratio is […]